Cargando…

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany

Coronary heart disease (CHD) remains the leading cause of death in Germany despite statin use to reduce low-density lipoprotein cholesterol (LDL-C) levels; improving lipids beyond LDL-C may further reduce cardiovascular risk. A fixed-dose combination of extended-release niacin (ERN) with laropiprant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michailov, Galin V., Davies, Glenn M., Krobot, Karl J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343242/ https://www.ncbi.nlm.nih.gov/pubmed/21465286 http://dx.doi.org/10.1007/s10198-011-0309-z

Ejemplares similares

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
por: Farnier, Michel, et al.
Publicado: (2014)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
por: Vosper, Helen
Publicado: (2011)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes
por: Brinton, Eliot A., et al.
Publicado: (2016)

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia
por: Hu, Miao, et al.
Publicado: (2015)

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
por: Bays, Harold E, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008)

Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin
por: Robinson, Jennifer G
Publicado: (2009)

Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
por: Lyseng-Williamson, Katherine A.
Publicado: (2012)

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
por: Le, Ngoc‐Anh, et al.
Publicado: (2013)

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
por: Insull, William, et al.
Publicado: (2010)

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial
por: Guyton, John R., et al.
Publicado: (2012)

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
por: Toth, Peter P, et al.
Publicado: (2012)

Hypophosphatemic effect of niacin extended release in ischemic kidney disease
por: Yasmeen, Ghazala, et al.
Publicado: (2015)

Erratum to: ‘Costs of treating cardiovascular events in Germany: a systematic literature review’
por: Schmid, Tamara, et al.
Publicado: (2016)

Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets
por: Milanowski, Bartłomiej, et al.
Publicado: (2020)

Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study
por: Kei, Anastazia, et al.
Publicado: (2011)

Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers
por: Zhang, Pingping, et al.
Publicado: (2015)

Efficacy of Laropiprant in Minimizing Brain Injury Following Experimental Intracerebral Hemorrhage
por: Ahmad, Abdullah Shafique, et al.
Publicado: (2017)

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
por: Haynes, Richard, et al.
Publicado: (2013)

Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation
por: Philipose, Sonia, et al.
Publicado: (2012)

Laropiprant attenuates EP(3) and TP prostanoid receptor-mediated thrombus formation
por: Philipose, Sonia, et al.
Publicado: (2012)

The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a)
por: Helmbold, Alan F., et al.
Publicado: (2010)

Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome
por: Chow, Dominic C, et al.
Publicado: (2008)

Niacin in Maize
por: Burkholder, Paul R., et al.
Publicado: (1944)

Effect of Niacin on Carotid Atherosclerosis in Patients at Low-Density Lipoprotein-Cholesterol Goal but High Lipoprotein (a) Level: a 2-Year Follow-Up Study
por: Song, Shinjeong, et al.
Publicado: (2019)

Evaluating the Release of Different Commercial Orally Modified Niacin Formulations In Vitro
por: Chbib, Christiane, et al.
Publicado: (2023)

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients
por: Yadav, Rahul, et al.
Publicado: (2015)

Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia
por: Kei, Anastazia, et al.
Publicado: (2014)

Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial
por: Paolini, J F, et al.
Publicado: (2008)

Effect of Extended Release Niacin on Cardiovascular Events and Kidney Function in Chronic Kidney Disease: A Post-Hoc Analysis of the AIM-HIGH Trial
por: Kalil, Roberto S., et al.
Publicado: (2015)

Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

Design and Evaluation of Niacin Microspheres
por: Maravajhala, Vidyavathi, et al.
Publicado: (2009)

Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBI-TER 2
por: Taylor, Allen J, et al.
Publicado: (2007)

Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
por: Zeman, Miroslav, et al.
Publicado: (2015)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
por: Goel, Harsh, et al.
Publicado: (2016)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
por: Dunbar, Richard L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2hu2bjnbcubd2c7t3vdaa2obct